Dispatch Bio

NEWS

NextGen

BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets

From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.

January 7, 2026

2 min read

Annalee Armstrong

Fashionable halftones collage. Startup business concept,fast business startup. Trendy modern retro illustration in bright trendy colors. Strategic planning concept and business success. Vector illustration

Startups

Dispatch Bio Launches With $216M To Develop Universal CAR T Therapy for Solid Tumors

Dispatch seeks to address two main challenges of immunotherapies in solid tumors: the lack of a target and the immunosuppressive tumor environment.

July 23, 2025

2 min read

Tristan Manalac

AWARDS

JOBS

IN THE PRESS

Press Releases

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

January 12, 2026

4 min read

Press Releases

Dispatch Bio Announces FDA Clearance of IND Application for DISP-10, a First-in-Class Immunotherapy Treatment, in Solid Tumors

January 12, 2026

3 min read

Press Releases

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

November 5, 2025

2 min read

Press Releases

Dispatch Bio Unveils First Clinical Program and Presents Data Supporting Flare Platform at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

November 5, 2025

3 min read

Press Releases

Dispatch Bio Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting

October 5, 2025

1 min read

Press Releases

Dispatch Bio Appoints Mauro Avanzi, M.D., Ph.D., as Chief Medical Officer

October 1, 2025

2 min read

Press Releases

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

July 23, 2025

6 min read